Vectura Group

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Vectura Group plc
Public (LSEVEC)
Industry Pharmaceuticals
Founded 1999
Headquarters Chippenham, UK
Key people
Bruno Angelici, Chairman
Christopher Blackwell, (CEO)
Revenue £58.0 million (2015)[1]
£(7.0) million (2015)[1]
£3.7 million (2015)[1]

Vectura Group plc (LSEVEC) is a leading British-based pharmaceuticals business. It is based in Chippenham and is a constituent of the FTSE 250 Index.


The company was formed in 1999 as a start-up pharmaceuticals business.[2] In 1999 it acquired Co-ordinated Drug Development and the Centre for Drug Formulation Studies.[2] In 2004 it was listed on the Alternative Investment Market.[2] In 2007 it acquired Innovata plc, another developer of pulmonary products,[3] and then moved on the full list of the London Stock Exchange.[2] It acquired Activaero, a German manufacturer in the same sector, for £108 million in March 2014.[4]


The Group is a developer of inhaled therapies for the treatment of respiratory diseases.[5]


  1. ^ a b c "Annual Report 2015" (PDF). Vectura Group. Retrieved 20 June 2015. 
  2. ^ a b c d "History". Vectura Group. Retrieved 20 June 2015. 
  3. ^ Vectura buys Innovata Guardian, 17 November 2006
  4. ^ "UK's Vectura buys Activaero for £108 million". Pharma Times. 16 March 2014. Retrieved 20 June 2015. 
  5. ^ "Dr Karl Keegan to join Vectura Group". Manufacturing chemist. Retrieved 20 June 2015. 

External links[edit]